Intracranial Aneurysms and Cognitive Function

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01320306

Enrollment

100

Registered

2011-03-22

Start date

2011-03-31

Completion date

2012-01-31

Last updated

2019-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intracranial Aneurysms

Brief summary

The prevalence rate of intracranial aneurysms in the adult population is close to 5%. Rupture risk of such aneurysms causing subarachnoid hemorrhage (SAH) can be substantial.Most patients suffering from an aneurysmal SAH are in their mid life, i.e., 30 to 60 years old. Aneurysmal SAH may cause disability and mortality. The present study includes a follow-up study and a cross-sectional fMRI study. The purpose of the follow-up study is to monitor patients receiving prophylactic surgical treatment of their un-ruptured aneurysms to examine whether such treatment is associated with cognitive, psychosocial and/or neurologic sequela. The purpose of the cross-sectional fMRI study is to examine the relationship between memory function and brain activity among SAH patients. Memory impairment is often found among aneurysmal SAH patients. Using fMRI can possibly shed some light on whether such memory impairment may be caused by diffuse cerebral damage or a focal damage at the aneurysm site.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Patients with un-ruptured aneurysms in the anterior communicating artery and the middle cerebral artery. * A subgroup of patients suffering aneurismal subarachnoid hemorrhage.

Exclusion criteria

* History of earlier cerebrovascular, psychiatric or neurological disease. * Age older than 75 years * Lack of fluency in Norwegian * Alcohol or Substance abuse * Aphasia * Substantial vision or hearing deficits

Design outcomes

Primary

Measure	Time frame	Description
Cognitive function	Each subject will undergo one assessment of cognitive function. The assessment lasts about 2.5 hours including breaks.	Neuropsychological Assessment

Secondary

Measure	Time frame	Description
Neurological status	Each subject will undergo one clinical assessment of neurological status.	A clinical examination of neurological status
fMRI	A subgroup of patients will participate in a fMRI study once	A subgroup of patients will participate in a fMRI study once

Countries

Norway

Outcome results